C₂N Diagnostics Unveils Breakthrough Alzheimer’s Blood Test

C₂N Diagnostics announced the planned launch of its new diagnostic blood test, PrecivityAD2, which uses mass spectrometry and a statistical algorithm to detect the two key drivers behind Alzheimer’s disease — tau and amyloid beta proteins.

The test calculates an amyloid probability score to detect whether a patient is positive or negative for brain amyloid plaques, which can cause this form of dementia. The test uses a blood sample instead of PET scans and spinal taps. 

The company said clinical studies show that the test is comparable to the current standards at a lower cost and with less discomfort to the patient.

PrecivityAD2 is a new version of the firm’s PrecivityAD, a test that calculates an amyloid beta ratio but does not detect tau.

C₂N Diagnostics intends to launch the new test in the first quarter of 2023.